Integrated Genomic Characterization of Endometrial Carcinoma
By D. Levine. Nature, 2013
5,292 citations recorded by the source corpus.
We performed an integrated genomic, transcriptomic and proteomic characterization of 373 endometrial carcinomas using array- and sequencing-based technologies. Uterine serous tumours and ∼25% of high-grade endometrioid tumours had extensive copy number alterations, few DNA methylation changes, low oestrogen receptor/progesterone receptor levels, and frequent TP53 mutations. Most endometrioid tumours had few copy number alterations or TP53 mutations, but frequent mutations in PTEN, CTNNB1, PIK3CA, ARID1A and KRAS and novel mutations in the SWI/SNF chromatin remodelling complex gene ARID5B. A subset of endometrioid tumours that we identified had a markedly increased transversion mutation frequency and newly identified hotspot mutations in POLE. Our results classified endometrial cancers into four categories: POLE ultramutated, microsatellite instability hypermutated, copy-number low, and copy-number high. Uterine serous carcinomas share genomic features with ovarian serous and basal-like breast carcinomas. We demonstrated that the genomic features of endometrial carcinomas permit a reclassification that may affect post-surgical adjuvant treatment for women with aggressive tumours.
Subfields: Molecular Biology, Obstetrics and Gynecology, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/7565c44949e7540ae885adeff6a97172a41de70a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Chuan He
- S. Roychowdhury
- Carien L. Creutzberg
- T. Bosse
- Remi A. Nout
- Elaine R. Mardis
- Mete Civelek
- Aldons J. Lusis
In Obstetrics and Gynecology
- Remi A. Nout
- S. Roychowdhury
- Carien L. Creutzberg
- T. Bosse
- Aldons J. Lusis
- Mete Civelek
- Jonathan A. Ledermann
- N. Colombo
In Reproductive Medicine
- S. Roychowdhury
- Carien L. Creutzberg
- T. Bosse
- Remi A. Nout
- Aldons J. Lusis
- Mete Civelek
- Jonathan A. Ledermann
- D. Querleu
Citations in the corpus
- m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer (2018, positive): “Sequencing studies have found that the METTL14 subunit of the core m 6 A methyltransferase complex is frequently mutated in endometrial tumors 36 , but the relevance of these mutations and of m 6 A mRNA methylation to the disease has not yet been established.”
- Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts (2016, background): “Similarly to our results, a previous report showed that endometrial carcinomas carrying a CTNNB1 mutation characterize a more aggressive subset within low-grade early-stage EEC (10, 22).”
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma (2020, methodology): “The reintroduction of carboplatin may be considered after a prolonged interval from the last platinum treatment, based on the results of a single-centre retrospective series in patients treated with a median platinum-free interval of 25 (8-79) months.”
- Precision Cancer Medicine: Challenges and Opportunities (2019, background): “cancer stem cell concentration increases, which both demonstrates the intrinsic resistance of these cells and accounts for rapid growth in relapse [18, 19].”
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency (2015, neutral): “tum, uterus, stomach, biliary tract, pancreas, ovary, prostate, and small intestine.(18,34-42) It is possible that patients with mismatch repair– deficient tumors of these types may also benefit from anti–PD-1 therapy, as may patients whose tumors contain other DNA repair deficiencies, such as those”
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics (2018, result): “Thus, the event time for OS and PFI derived from this TCGA dataset is consistent with the literature, an observation previously noted for OS in the initial GBM marker paper when only 185 cases were analyzed (Cancer Genome Atlas Research Network, 2008).”